UBS South Africa (PTY) Limited Form 8.5 (EPT/NON-RI) - Mediclinic International p (6727A)
2023年5月25日 - 7:26PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMMDC
RNS Number : 6727A
UBS South Africa (PTY) Limited
25 May 2023
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI")
STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: UBS South Africa (Pty) Limited
(b) Name of offeror/offeree in relation to whose relevant securities this form Mediclinic International plc
relates:
Use a separate form for each offeror/offeree
-------------------------------
(c) Name of the party to the offer with which exempt principal trader is connected: Mediclinic International plc
-------------------------------
(d) Date position held/dealing undertaken: 24 May 2023
For an open position disclosure, state the latest practicable date prior to the
disclosure
-------------------------------
(e) In addition to the company in 1(b) above, is the exempt principal trader making No
disclosures
in respect of any other party to this offer?
If it is a cash offer or possible cash offer, state "N/A"
-------------------------------
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing (if any)
Class of relevant security: Ordinary npv
Interests Short positions
----------------- ------------------
Number % Number %
------- -------- --------- -------
5808 0.0008% 0 0.00%
------- -------- --------- -------
(2) Cash-settled derivatives: 0 0.00% 0 0.00%
------- -------- --------- -------
(3) Stock-settled derivatives (including options) and agreements to
purchase/sell: 0 0.00% 0 0.00%
------- -------- --------- -------
TOTAL: 5808 0.0008% 0 0.00%
------- -------- --------- -------
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(b), copy
table 2(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchase/sale Total number of Highest price per unit Lowest price per unit
security securities paid/received paid/received
Ordinary npv Purchase 38573 117.95 ZAR 117.95 ZAR
-------------- ------------------------ ------------------------ ------------------------
Ordinary npv Sale 15878 118.45 ZAR 118.43 ZAR
-------------- ------------------------ ------------------------ ------------------------
TOTAL BUY : 38573 117.95 ZAR 117.95 ZAR
-------------- ------------------------ ------------------------ ------------------------
TOTAL SELL: 15878 118.45 ZAR 118.43 ZAR
-------------- ------------------------ ------------------------ ------------------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise price Type Expiry date Option money
description purchasing, securities to per unit e.g. American, paid/ received
e.g. call selling, which option European etc. per unit
option varying etc. relates
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt
principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 25 May 2023
Contact name: Ruven Raghoo
----------------
Telephone number: +27 11 322 7258
----------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's dealing disclosure
requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FEOBGGDUUDDDGXU
(END) Dow Jones Newswires
May 25, 2023 06:26 ET (10:26 GMT)
Mediclinic (LSE:MDC)
過去 株価チャート
から 11 2024 まで 12 2024
Mediclinic (LSE:MDC)
過去 株価チャート
から 12 2023 まで 12 2024
